Stay updated on Cabozantinib and Durvalumab Immuno-oncology Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Minor version update from v3.4.1 to v3.4.2; study details and page layout remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T13:40:44.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The page revision label changed from v3.4.0 to v3.4.1.
    Difference
    0.1%
    Check dated 2026-02-05T23:12:13.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Revision history updated: added Revision: v3.3.4 and removed Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T04:47:57.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    Footer updates: added Revision: v3.3.3 and removed the HHS Vulnerability Disclosure and Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-24T14:44:11.000Z thumbnail image
  6. Check
    91 days ago
    Change Detected
    Summary
    Publications section updated to state that publications are provided by the entry author and are about the study results; PubMed auto-fill remains, and the revision tag was updated from v3.2.0 to v3.3.2.
    Difference
    0.2%
    Check dated 2025-11-25T14:16:03.000Z thumbnail image
  7. Check
    99 days ago
    Change Detected
    Summary
    Removed the banner notice about a lapse in government funding on the ClinicalTrials.gov page for ARCADIA (NCT03824691), which is an administrative detail rather than core study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T07:25:21.000Z thumbnail image

Stay in the know with updates to Cabozantinib and Durvalumab Immuno-oncology Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Durvalumab Immuno-oncology Clinical Trial page.